LifeMD, Inc. (LFMDP) stock analysis
Close on Oct 30, 2026Market cap $110.38MP/E –Yield –
StockData Score
Prices as of Oct 30, 2026How the score works
Mixed10 of 30 checks passed
LifeMD passes 10 of the 30 checks behind our score; 13 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 3/6
- Past performance
- 3/6
- Financial health
- 4/6
- Dividend
- 0/6
What stands out
No debt
LifeMD has no borrowings on its latest balance sheet.
Revenue growing 10%+ a year
Revenue grew 17.7% a year over the last three fiscal years.
Interest well covered
No meaningful interest expense to cover.
Debt covered by cash flow
There is no debt to cover.
What to watch
Margin of safety under 20%
The price is 98.6% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $2.29 is above our fair value estimate of $1.15.
Elevated bankruptcy risk
The Altman Z-score is -3.15; above 3 is the safe zone and below 1.8 the distress zone.
Guidance lowered
LifeMD lowered its full year 2026 Revenue outlook on Aug 5, 2026.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B above the industry
LifeMD's price-to-book of 13.86 is above the Health Services median of 3.37.
Trading above fair value
The share price of $2.29 is above our fair value estimate of $1.15.
Margin of safety under 20%
The price is 98.6% above fair value, so there is no margin of safety.
Growth3/6
Revenue growing 10%+ a year
Revenue grew 17.7% a year over the last three fiscal years.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing faster than the industry
Revenue grew 3.8% over the last twelve months; the Health Services median is 0.3%.
Guidance lowered
LifeMD lowered its full year 2026 Revenue outlook on Aug 5, 2026.
Gross margin improving
Gross margin was 86.1% over the last twelve months, against 83.1% a year earlier.
Past performance3/6
Return on equity
Needs positive equity and five years of results.
Return on invested capital
Needs operating income and invested capital.
Return on equity above the industry
LifeMD's return on equity of 6.5% is above the Health Services median of -2.6%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin above its 5-year average
Net margin was 0.1% over the last twelve months, against a 5-year average of -24.8%.
Net margin above the industry
LifeMD's net margin of 0.1% is above the Health Services median of -6.3%.
Financial health4/6
No debt
LifeMD has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets don't cover short-term debts
Current assets are 0.90 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is -3.15; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
LifeMD has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$1.15
The share price is 99% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/B | 3.4× | – | 3.4× | $0.56 | 40% |
| P/Sleft out, too far from the others | 1.4× | 1.2× | 1.6× | $4.65 | – |
| Earnings power | 13.9% cost of equity | – | – | $1.55 | 60% |
| Fair value | $1.15 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/B at month end
- Health Services median 3.4
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
High risk
- Average value traded per day
- $1.78M
- Value traded per 1% price move
- $741.16K
Downside
High risk
- Typical loss in a bad month
- 33.8%
- Volatility (annualized)
- 80%
- Sharpe ratio, 1 year
- -0.84
- Beta to the S&P 500 (5Y)
- 1.78
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +25.3% | +17.7% | +39.1% | +66.0% | |
| Gross profit | +24.7% | +18.3% | +42.4% | +67.3% | |
| Free cash flow | -60.1% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 868.3% | 3565.1% | 204.0% | |
| Return on assets | -178.9% | -696.1% | 19.6% | |
| Current ratio | 0.69 | 0.89 | 1.25 | |
| Debt to equity | – | – | – | |
| Interest coverage | -24.2× | -34.7× | -5.6× | |
| Inventory turnover | 17.6× | 8.0× | 9.9× | |
| Capex to revenue | – | – | 1.0% | |
| Diluted shares | 7M | 14M | 45M |
Where the cash went
Fiscal 2021 to 2025, five years combined
LifeMD generated $90.63M from operations and spent $17.72M on capital expenditure, dividends and share buybacks. 23% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 7.4% | 2.65× | 10.41× | 204.0% |
| FY2024 | -13.8% | 2.30× | -24.13× | 767.6% |
| FY2023 | -13.5% | 3.63× | -10.66× | 522.1% |
| FY2022 | -38.3% | 3.15× | 6.66× | -802.8% |
| FY2021 | -65.6% | 2.93× | 3.10× | -595.9% |
| FY2020 | -157.3% | 4.43× | -5.12× | 3565.1% |
| FY2019 | -25.2% | 4.11× | -67.00× | 6934.2% |
| FY2018 | -14.9% | 4.29× | 2.18× | -139.4% |
| FY2017 | -32.8% | 3.59× | 3.90× | -457.9% |
| FY2016 | -21.1% | 8.46× | -4.85× | 868.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$14.35M
- Cash generatingOperating cash flow above zero$8.28M
- Return on assets improvedROA up on the prior year-36.6% → 18.9%
- Earnings backed by cashOperating cash flow above net income$8.28M vs $14.35M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.78 → 1.25
- No dilutionShare count did not rise41M → 45M
- Gross margin improvedGross margin up on the prior year86.15% → 85.72%
- More efficientAsset turnover rose2.65 → 2.55